Brings together all of the latest research by top researchers on molecular mechanisms in the pathogenesis of INS

Represents one putative pathogenetic molecule in each chapter and reviews its role, mechanism, and prospects as a biomaker or for new drugs

Provides valuable reading for physicians, pediatricians, nephrologists, and individuals researching nephrotic syndrome

Part 1. Introduction.- 1. History of Research on Pathogenesis of Idiopathic Nephrotic Syndrome.- Part 2. Minimal-change nephrotic syndrome (MCNS).- 2. Hemopexin in Minimal Change Nephrotic Syndrome.- 3. Angiopoietin-like-4 (Angptl4) in MCNS.- 4. Co-stimulatory molecule CD80 (B7.1) in MCNS.- 5. Energy and Mammalian target of rapamycin complex 1 (mTORC1) in minimal change nephrotic syndrome.- 6. The role of c-mip in the pathogenesis of Minimal Change Nephrotic Syndrome.- 7. REGULATORY T-CELLS AND OXIDATIVE STRESS IN MINIMAL CHANGE NEPHROPATHY.- 8. CYTOKINES AS ACTIVE FACTORS IN MINIMAL CHANGE NEPHROTIC SYNDROME.- Part 3. Focal segmental glomerulosclerosis (FSGS).- 9. Soluble urokinase-type plasminogen activator receptor (suPAR) in Focal Segmental Glomerulosclerosis.- 10. CYTOKINES AS ACTIVE FACTORS IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS.- Part 4. Idiopathic Membranous Nephropathy (IMN).- 11. M-Type Phospholipase A2 Receptor (PLA2R) and Thrombospondin Type-1 Domain-Containing 7A (THSD7A) in Membranous Nephropathy.- 12. Cationic Bovine Serum Albumin as Cause of Membranous Nephropathy: From Mice to Men.- Part 5. Treatment in Idiopathic Nephrotic Syndrome.- 13. Podocytes as a direct target of drugs used in Idiopathic Nephrotic Syndrome.